Diseases [C] » Respiratory Tract Diseases [C08] » Lung Diseases » Lung Diseases, Interstitial » Pulmonary Fibrosis » Idiopathic Pulmonary Fibrosis
Diseases [C] » Respiratory Tract Diseases [C08] » Lung Diseases » Lung Diseases, Interstitial » Pulmonary Fibrosis » Idiopathic Pulmonary Fibrosis » Idiopathic Interstitial Pneumonias » Idiopathic Pulmonary Fibrosis
Description
A common interstitial lung disease of unknown etiology, usually occurring between 50-70 years of age. Clinically, it is characterized by an insidious onset of breathlessness with exertion and a nonproductive cough, leading to progressive DYSPNEA. Pathological features show scant interstitial inflammation, patchy collagen fibrosis, prominent fibroblast proliferation foci, and microscopic honeycomb change. MeSH
Hierarchy View
Subtype Terms (2)
Hamman-Rich Syndrome
1 experimental drug
Idiopathic Interstitial Pneumonias
3 drugs (1 approved, 2 experimental)
Approved Indicated Drugs (5)
Phase 4 Indicated Drugs (2)
Phase 3 Indicated Drugs (18)
Phase 2 Indicated Drugs (45)
Phase 1 Indicated Drugs (33)
Other Experimental Indicated Drugs (6)
Organization Involved with Phase 4 Indications (8)
Organization Involved with Phase 3 Indications (41)
Organization Involved with Phase 2 Indications (88)
Beijing Kawin Technology Share-Holding Co., Ltd.
Bharat Biotech International Limited
Bombay Hospital & Medical Research Center
Chinese Academy of Medical Sciences
Coalition for Pulmonary Fibrosis
Conselho Nacional de Desenvolvimento Científico e Tecnológico
Cumballa Hill Hospital And Heart Institute
Daw Park Repatriation, Australia
Dunedin Public Hospital, New Zealand
Federal Research Clinical Center of Federal Medical & Biological Agency, Russia
Global Blood Therapeutics, Inc.
Huazhong University of Science and Technology
Icahn School of Medicine at Mount Sinai
Institut National de la Santé Et de la Recherche Médicale, France
Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
National Center for Advancing Translational Science (NCATS)
National Institutes of Health (NIH)
P.D. Hinduja Hospital and Medical Research Centre, Mumbai
Rajiv Gandhi University of Health Sciences
Sri Bala Medical Centre and Hospital, India
Organization Involved with Phase 1 Indications (31)
Organization Involved with Other Experimental Indications (15)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
